Weight regain after stopping GLP-1 drugs: what the data says

What did @cesar_contrerasjr actually say?

The creator is stitching a clip about weight regain after stopping GLP-1 medications like Mounjaro or Ozempic. His core argument: yes, you regain weight when you stop, but that's true of any diet or pill. His proposed solution is to use unspecified "tools" to build habits while simultaneously improving insulin sensitivity, until your body "does what it's supposed to do naturally" and you no longer need the medication or a strict diet.

He's essentially making two connected claims: first, that insulin resistance is the underlying driver of the weight problem, and second, that restoring insulin sensitivity is the exit ramp off GLP-1 medications without the rebound. He says "when you manage your insulin, you could actually not be dependent on other medications." That's a bold claim, and it deserves a hard look.

Does the science back this up?

Partly, but the framing is too clean. The weight regain part is accurate and well-documented. The insulin sensitivity piece has real science behind it, but it doesn't tell the full story of why people regain weight after stopping GLP-1s.

On regain: Wilding et al. (2022, Diabetes Care) followed semaglutide users after drug discontinuation and found participants regained roughly two-thirds of their lost weight within a year. Some studies report even higher rebound in certain individuals, which tracks with the "double the weight" anecdote, though that specific figure isn't a study average.

On insulin sensitivity: GLP-1 receptor agonists do improve insulin sensitivity, and this effect has been measured independently of weight loss. Nauck et al. (2021, Nature Reviews Endocrinology) confirmed that GLP-1 improves beta-cell function and reduces insulin resistance. But insulin sensitivity is not the primary reason people lose weight on these drugs. GLP-1s suppress appetite through central nervous system pathways, slow gastric emptying, and reduce caloric intake directly. When the drug stops, those appetite-regulating signals stop too, regardless of insulin status.

What did they get wrong (or right)?

He got the regain problem right. Credit where it's due: the rebound is real, it's documented, and the "moment you stop, you get it all back" framing is directionally accurate for a large portion of users. That's a fair point to make publicly.

Where things go sideways is the insulin sensitivity exit ramp theory. The creator implies that once you're "insulin sensitive again, your body does what it's supposed to do naturally" and weight management becomes self-sustaining. This overstates what insulin sensitivity alone can accomplish.

Obesity involves dysregulation of leptin signaling, hypothalamic appetite circuits, and adipose tissue biology that persist after weight loss regardless of insulin status. Sumithran et al. (2011, New England Journal of Medicine) showed that hunger hormones like ghrelin remain elevated and satiety hormones remain suppressed for at least a year after weight loss, creating a sustained biological drive to regain. Improved insulin sensitivity doesn't override that.

He also never specifies what his "tools" are. That vagueness is doing a lot of work in this video, and it's a red flag. Promising an off-ramp from GLP-1 dependence without naming the intervention is not a health claim, it's a sales pitch.

What should you actually know?

GLP-1 medications are currently understood to require long-term or indefinite use for sustained weight management in most people. That's not a pharma talking point, it's the clinical consensus emerging from discontinuation data. The American Diabetes Association and Endocrine Society both treat obesity as a chronic condition requiring ongoing management, not a fixable state you graduate out of.

That said, the broader point about lifestyle habits mattering is not wrong. Muscle mass, diet quality, sleep, and activity level all influence insulin sensitivity and metabolic health. Building those habits while on a GLP-1 is genuinely useful. Some patients do successfully taper or discontinue with careful medical supervision and maintained lifestyle changes, but this is not guaranteed and not explained by insulin sensitivity alone.

If you're considering stopping a GLP-1 medication, that decision belongs with your prescribing clinician, not a TikTok creator promoting unnamed tools. Weight regain after discontinuation is a known, documented risk that should be part of any informed conversation before you start the medication, not a surprise when you stop it.